Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer’s disease. Lancet 397:1577–1590

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954–963

Article  CAS  PubMed  Google Scholar 

Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185

Article  CAS  PubMed  ADS  Google Scholar 

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562

Article  PubMed  PubMed Central  Google Scholar 

Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17:580–589

Article  PubMed  Google Scholar 

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM (2019) Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology 93:e1635–e1646

Article  PubMed  Google Scholar 

Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, Doecke J, Maruff P, Martins RN, Ames D, Rowe CC, Masters CL, Villemagne VL (2019) Application of the NIA-AA research framework: towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study. J Prev Alzheimers Dis 6:248–255

CAS  PubMed  Google Scholar 

Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, Festari C, Ribaldi F, Scheffler M, Schibli R, Schwarz AJ, Zekry D, Lovblad KO, Boccardi M, Unschuld PG, Gold G, Frisoni GB, Garibotto V (2020) The A/T/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging 47:247–255

Article  CAS  PubMed  Google Scholar 

Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, Lowe VJ, Vemuri P, Machulda MM, Schwarz CG, Gunter JL, Senjem ML, Graff-Radford J, Jones DT, Roberts RO, Rocca WA, Petersen RC (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321:2316–2325

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasuga K, Tsukie T, Kikuchi M, Tokutake T, Washiyama K, Shimizu S, Yoshizawa H, Kuroha Y, Yajima R, Mori H, Arakawa Y, Onda K, Miyashita A, Onodera O, Iwatsubo T, Ikeuchi T, Japanese Alzheimer’s Disease Neuroimaging I (2023) The clinical application of optimized AT(N) classification in Alzheimer’s clinical syndrome (ACS) and non-ACS conditions. Neurobiol Aging 127:23–32

Article  CAS  PubMed  Google Scholar 

Pascoal TA, Leuzy A, Therriault J, Chamoun M, Lussier F, Tissot C, Strandberg O, Palmqvist S, Stomrud E, Ferreira PCL, Ferrari-Souza JP, Smith R, Benedet AL, Gauthier S, Hansson O, Rosa-Neto P (2023) Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease. Alzheimers Dement (Amst) 15:e12390

Article  PubMed  PubMed Central  Google Scholar 

Peretti DE, Ribaldi F, Scheffler M, Chicherio C, Frisoni GB, Garibotto V (2023) Prognostic value of imaging-based ATN profiles in a memory clinic cohort. Eur J Nucl Med Mol Imaging 50(11):3313–3323

Article  PubMed  PubMed Central  Google Scholar 

Therriault J, Gauthier S, Rosa-Neto P (2023) Adding the topographical information from Tau-PET to the A/T/(N) framework: steps towards staging AD in vivo. J Prev Alzheimers Dis 10:381–386

CAS  PubMed  Google Scholar 

Wang ZB, Tan L, Gao PY, Ma YH, Fu Y, Sun Y, Yu JT, Alzheimer’s Disease Neuroimaging I (2023) Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer’s disease neuropathology at autopsy. Alzheimers Dement 19(10):4421–4435

Article  CAS  PubMed  Google Scholar 

Erickson P, Simren J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H, Cohort A (2023) Prevalence and clinical implications of a beta-amyloid-negative, tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease. JAMA Neurol 80(9):969–979

Article  PubMed  PubMed Central  Google Scholar 

Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Berckel BNM, van der Flier WM (2020) ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology 95:e46–e58

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oberstein TJ, Schmidt MA, Florvaag A, Haas AL, Siegmann EM, Olm P, Utz J, Spitzer P, Doerfler A, Lewczuk P, Kornhuber J, Maler JM (2022) Amyloid-beta levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain 145:4032–4041

Article  PubMed  PubMed Central  Google Scholar 

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9:197–210

CAS  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, Investigators T-A (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512–527

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21

Article  PubMed  Google Scholar 

Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G (2022) “Real-world” eligibility for aducanumab depends on clinical setting and patients’ journey. J Am Geriatr Soc 70:626–628

Article  PubMed  Google Scholar 

Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M (2021) “Real world” eligibility for aducanumab. J Am Geriatr Soc 69:2995–2998

Article  PubMed  Google Scholar 

Epelbaum S, Paquet C, Hugon J, Dumurgier J, Wallon D, Hannequin D, Jonveaux T, Besozzi A, Pouponneau S, Hommet C, Blanc F, Berly L, Julian A, Paccalin M, Pasquier F, Bellet J, Boutoleau-Bretonniere C, Charriau T, Rouaud O, Madec O, Mouton A, David R, Bekadar S, Fabre R, Liegey E, Deberdt W, Robert P, Dubois B (2019) How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years. BMJ Open 9:e029663

Article  PubMed  PubMed Central  Google Scholar 

American Psychiatric Association (2022) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishin, Washington, DC, US

Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36:268–272

Article  CAS  PubMed  Google Scholar 

Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 149:351–356

Article  CAS  PubMed  Google Scholar 

Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR (2006) Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol 63:1627–1631

Article  PubMed  Google Scholar 

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55:967–972

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21:2618–2625

Article  PubMed  PubMed Central  Google Scholar 

Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D, Alzheimer’s Disease Neuroimaging Initiative ftAIMNdTANS-Gc, Schillaci O, Berti V, Calcagni ML, Cistaro A, Morbelli S, Nobili F, Pappata S, Volterrani D, Gobbo CL (2021) Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med Mol Imaging 48:2486–2499

Article  CAS  PubMed  Google Scholar 

Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362–377

CAS  PubMed  PubMed Central  Google Scholar 

Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, Sabbagh M, Selkoe D, Weiner M, Salloway S (2022) Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis 9:221–230

CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg A, Ohlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryden M, Thunborg C, Wiggenraad F, Sandebring-Matton A, Solomon A, Kivipelto M (2022) beta-Amyloid, Tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology 99:e2102–e2113

Article  CAS  PubMed